Grace Therapeutics, Inc. (GRCE)

NASDAQ: GRCE · USD

$1.95

+0.08 (+4.3%)· Recorded snapshot

Market cap	41M
Net income (ttm)	-20.2M
EPS (ttm)	-$1.20
Shares out	21M
Volume	161,351
Beta	0.33

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -20.2M
EPS (ttm): -$1.20
Market cap: 41M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-36.2

P25 n/aP50 n/aP75 n/a

ROIC-11.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All GRCE indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001444192
Company name	Grace Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	00439U104
Earnings date	2026-11-12
Earnings time	bmo
Employees	5
Employees change	-1
Employees growth	-16.67%
Enterprise value	$27.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	March
Founded	2002
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US00439U1043
Last 10-K release date	2026-06-18
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2023-07-10
Last stock split type	Reverse
Market cap	$41M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	Yes
Price	$1.95
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	GRCE
U.S. state	New Jersey
Website	https://www.gracetx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-61.55%
FCF / EV yield	-37.88%
FCF yield	-25.15%
P/B ratio	0.63x
Price / tangible book value	3.28x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-4M
ROA	-10.81%
ROA (5Y)	-10.5%
ROCE	-21.24%
ROE	-36.19%
ROE (5Y)	-21.36%
ROIC	-11.6%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Net income growth years	3
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$7,000
EBIT	$-10.4M
EBITDA	$-10.4M
EPS	$-1.20
FCF per share	$-0.49
Financing cash flow	$4M
Free cash flow	$-10.3M
Free cash flow minus SBC	$-10.9M
Income taxes	$-1.7M
Net cash flow	$-6.2M
Net income	$-20.2M
Operating cash flow minus SBC	$-10.9M
Operating income	$-10.4M
Stock-based compensation	$601,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.96
Debt / equity	0
Goodwill	$8.1M
Long-term assets	$35.7M
Long-term liabilities	$612,000
Net cash (debt)	$13.8M
Net cash / market cap	33.62%
Net cash growth	-31.24%
Net debt / equity	-0.29
Piotroski F-Score	2
Property, plant and equipment	$7,000
Shareholders' equity	$48.2M
Tangible book value	$12.5M
Tangible book value per share	$0.77
Total assets	$50.1M
Total cash	$13.8M
Total debt	$0
Total liabilities	$1.9M
WACC	6.08%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$14.3M
Current liabilities	$1.3M
Current ratio	11.47
Net working capital	$-673,000
Quick ratio	11.02
Working capital	$13.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-26.33%
Dividend yield	0%
Shareholder yield	-26.33%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-97.1%
10Y return CAGR	-29.83%
10Y total return	-97.1%
150-day SMA	$2.48
15Y price change	-99.67%
15Y return CAGR	-31.66%
15Y total return	-99.67%
1D price change	4.28%
1M price change	-8.02%
1M total return	-8.02%
1W price change	-1.52%
1W total return	-1.52%
1Y price change	-38.1%
1Y return CAGR	-38.12%
1Y total return	-38.1%
20-day SMA	$1.98
200-day SMA	$2.83
3M price change	-15.22%
3M total return	-15.22%
3Y price change	-18.75%
3Y return CAGR	-6.69%
3Y total return	-18.75%
50-day SMA	$2.08
50-day SMA vs 200-day SMA	50under200
52-week high	$5.18
52-week high date	2026-04-02
52-week low	$1.67
52-week low date	2026-10-26
5Y price change	-80.54%
5Y return CAGR	-27.92%
5Y total return	-80.54%
6M price change	-9.72%
6M total return	-9.72%
All-time high	$2,016.00
All-time high date	2013-07-24
All-time low	$1.67
All-time low date	2026-10-26
Average true range (ATR)	$0.12
Average volume	124.9K
Beta (1Y)	0.57
Beta (2Y)	1.14
Beta (5Y)	0.33
Change from 52-week high	-62.36%
Change from 52-week low	16.77%
Change from all-time high	-99.9%
Change from all-time low	16.77%
Change from open	3.17%
Day's gap	1.07%
Dollar volume	$314,634
High price	$1.96
Low price	$1.88
Monthly RSI	39.32
Open price	$1.89
Position in 52-week range	87.5%
Premarket change	-1.6%
Premarket close	$1.87
Premarket price	$1.84
Previous close	$1.87
Price vs 150-day SMA	-21.28%
Price vs 20-day SMA	-1.27%
Price vs 200-day SMA	-31.19%
Price vs 50-day SMA	-6.34%
Relative volume	1.29
RSI	46.58
Sharpe ratio	-0.3
Sharpe ratio (3Y)	0.2
Sharpe ratio (5Y)	-0.17
Sortino ratio	-0.29
Sortino ratio (3Y)	0.37
Sortino ratio (5Y)	-0.18
Volume	161.4K
Weekly RSI	38.49
YTD price change	-43.64%
YTD total return	-43.64%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	13.3M
Float percentage	63.17%
Shares change (QoQ)	0.08%
Shares change (YoY)	26.33%
Shares held by insiders	16.67%
Shares held by institutions	18.41%
Shares outstanding	21M
Short % of float	12.67%
Short % of shares	8%
Short ratio	11.8 days

Deeper analysis on GRCE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this GRCE report

Is a complete GRCE research report available?

No complete published report is available for Grace Therapeutics, Inc. (GRCE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Grace Therapeutics, Inc. (GRCE)

Price

Financial snapshot

Fair-value bridge

Latest news · GRCE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All GRCE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on GRCE

Frequently asked questions